Terrain Biosciences

Terrain Biosciences focuses on RNA medicine development, leveraging AI and machine learning to optimize RNA sequences for therapeutic applications in the biopharmaceutical sector. Terrain Biosciences, Inc. is a biotechnology company that was founded in 2023 and is headquartered in Cambridge, US. In January 2026, Eclipse Bioinnovations, Inc.

, a portfolio company of Alexandria Venture Investments, iGlobe Partners, Photon Ventures, and Phoenix Venture Partners, acquired Terrain Biosciences from Magnetic. Financial terms of the transaction were not disclosed. The founder's background details are not publicly available, nor are there mentions of prior companies founded by them. Terrain Bio specializes in RNA medicine development, offering a suite of products and services focused on optimizing RNA sequences for therapeutic applications.

Their core offerings include a comprehensive AI/ML design suite that enables clients to tailor nucleotide sequences by enhancing manufacturability, stability, expression quality, immunogenicity, durability, and targetability. This technology is utilized in the design and production of messenger RNA (mRNA) sequences, catering to biopharmaceutical companies and research institutions aiming to expedite the drug discovery process. Terrain Bio's innovative manufacturing platform facilitates the production of mRNA at microgram to gram scales, ensuring high-quality outputs for rapid experimental iterations and translational studies. The company serves a global clientele, primarily within North America and Europe, focusing on biopharma teams dedicated to advancing healthcare solutions through RNA-based therapies.

Terrain Bio's revenue model is built around B2B transactions, primarily engaging with biopharmaceutical companies that require customized mRNA solutions for their research and development efforts. The company operates through partnerships and direct contracts, where clients can access services such as custom-built RNA and catalog mRNA offerings. Pricing structures are tailored to the specific needs of clients based on the complexity and scale of the mRNA sequences required. Terrain Bio engages in negotiated agreements that outline service deliverables and project timelines, fostering long-term relationships with its partners in the biotech sector.

While specific pricing details are not disclosed, the company's commitment to delivering high-quality RNA products positions it favorably in the competitive landscape of RNA therapeutics. The acquisition aims to expand its integrated platform by adding AI-enabled RNA design and manufacturing analytics to accelerate data-driven RNA therapeutic development.